 | NEUROIMMUNOMODULATION: MOLECULAR ASPECTS, INTEGRATIVE SYSTEMS, AND CLINICAL ADVANCES
Copyright © 1998 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 840:684-697 (1998)
© 1998 New York Academy of Sciences
Evidence for and Pathophysiologic Implications of Hypothalamic-Pituitary-Adrenal Axis Dysregulation in Fibromyalgia and Chronic Fatigue Syndrome
MARK A. DEMITRACKa,b AND
LESLIE J. CROFFORDc
bLilly Research Laboratories, Lilly Corporate Center, Indianapolis, Indiana 46285 USA
cDepartment of Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, Michigan 48109 USA
aAdditional correspondence information: Telephone: 317-277-2443; Fax: 317-277-9551; e-mail: madmd{at}lilly.com
Chronic fatigue syndrome (CFS) is characterized by profound fatigue anad an array of diffuse somatic symptoms. Our group has established that impaired activation of the hypothalamic-pituitary-adrenal (HPA) axis is an essential neuroendocrine feature of this condition. The relevance of this finding to the pathophysiology of CFS is supported by the observation that the onset and course of this illness is excerbated by physical and emotional stressors. It is also notable that this HPA dysregulation differs from that seen in melancholic depression, but shares features with other clinical syndromes (e.g., fibromyalgia). How the HPA axis dysfunction develops is unclear, though recent work suggests disturbances in serotonergic neurotransmission and alterations in the activity of AVP, an important co-secretagogue that, along with CRH, influences HPA axis function. In order to provide a more refined view of the nature of the HPA dusturbance in patients with CFS, we have studied the detailed, pulsatile characteristics of the HPA axis in a group of patients meeting the 1994 CDC case criteria for CFS. Results of that work are consistent with the view that patients with CFS have a reduction of HPA axis activity due, in part, to impaired central nervous system drive. These observations provide an important clue to the development of more effective treatment to this disabling condition.
This article has been cited by other articles:
|
|
|
|
 
P. SARZI-PUTTINI, F. ATZENI, A. DIANA, A. DORIA, and R. FURLAN
Increased Neural Sympathetic Activation in Fibromyalgia Syndrome
Ann. N.Y. Acad. Sci.,
June 1, 2006;
1069(1):
109 - 117.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Di Giorgio, M. Hudson, W. Jerjes, and A. J. Cleare
24-Hour Pituitary and Adrenal Hormone Profiles in Chronic Fatigue Syndrome
Psychosom Med,
May 1, 2005;
67(3):
433 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Bower, P. A. Ganz, and N. Aziz
Altered Cortisol Response to Psychologic Stress in Breast Cancer Survivors With Persistent Fatigue
Psychosom Med,
March 1, 2005;
67(2):
277 - 280.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. I. WEBSTER, M. MOAYERI, and E. M. STERNBERG
Novel Repression of the Glucocorticoid Receptor by Anthrax Lethal Toxin
Ann. N.Y. Acad. Sci.,
June 1, 2004;
1024(1):
9 - 23.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Skapinakis, G. Lewis, and V. Mavreas
Temporal Relations Between Unexplained Fatigue and Depression: Longitudinal Data From an International Study in Primary Care
Psychosom Med,
May 1, 2004;
66(3):
330 - 335.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Kennedy, V. Spence, F. Khan, and J. J. F. Belch
Plasma endothelin-1 levels in chronic fatigue syndrome
Rheumatology,
February 1, 2004;
43(2):
252 - 253.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Logan
Dietary Modifications and Fibromyalgia
Complementary Health Practice Review,
October 1, 2003;
8(3):
234 - 245.
[Abstract]
[PDF]
|
|
|
|
|
|
|
A. J. Cleare
The Neuroendocrinology of Chronic Fatigue Syndrome
Endocr. Rev.,
April 1, 2003;
24(2):
236 - 252.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. S. Goldstein, D. Robertson, M. Esler, S. E. Straus, and G. Eisenhofer
Dysautonomias: Clinical Disorders of the Autonomic Nervous System
Ann Intern Med,
November 5, 2002;
137(9):
753 - 763.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Ursin and H. R. Eriksen
Sensitization, Subjective Health Complaints, and Sustained Arousal
Ann. N.Y. Acad. Sci.,
March 1, 2001;
933(1):
119 - 129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Van Houdenhove, E. Neerinckx, R. Lysens, H. Vertommen, L. Van Houdenhove, P. Onghena, R. Westhovens, and M.-B. D'Hooghe
Victimization in Chronic Fatigue Syndrome and Fibromyalgia in Tertiary Care: A Controlled Study on Prevalence and Characteristics
Psychosomatics,
February 1, 2001;
42(1):
21 - 28.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. J. Cleare, S. S. Sookdeo, J. Jones, V. O’Keane, and J. P. Miell
Integrity of the Growth Hormone/Insulin-Like Growth Factor System Is Maintained in Patients with Chronic Fatigue Syndrome
J. Clin. Endocrinol. Metab.,
April 1, 2000;
85(4):
1433 - 1439.
[Abstract]
[Full Text]
|
|
|
|
